...
首页> 外文期刊>Iranian Journal of Immunology >Expression of Recombinant Heat-Shock Protein 70 of MCAN/IR/96/LON-49, a Tool for Diagnosis and Future Vaccine Research
【24h】

Expression of Recombinant Heat-Shock Protein 70 of MCAN/IR/96/LON-49, a Tool for Diagnosis and Future Vaccine Research

机译:诊断和未来疫苗研究的工具MCAN / IR / 96 / LON-49重组热休克蛋白70的表达

获取原文
           

摘要

Background: Heat shock protein 70 (HSP70) is present in all organisms studied so far, and is a major immunogen in infections caused by pathogens including Leishmania spp. Objective: The aim of this study was to clone and express HSP70 from L. infantum strain MCAN/IR/96/LON-49 and evaluate antibody response against HSP70 in visceral leishmaniasis (VL). Methods: The L. infantum HSP70 gene segment was amplified by specific primers. It was cloned into pTZ57R vector and subcloned into pET32a (+) expression vector. The new construct was transformed in the E.coli Rosetta strain, and HSP70 protein was expressed in the presence of 1 mM IPTG and purified using a HiTrap chelating column. Antibody responses against HSP70 were determined by ELISA in 37 patients with visceral leishmaniasis and 63 healthy controls. Results: Expression of HSP70 protein was confirmed using SDS-PAGE electrophoresis and dot blot with an anti-His tag antibody. There was no difference between the sequence of nucleotides of the HSP70 gene in the present study and other reported sequences. The ELISA results indicated that the sera of 81.1% (30/37) of the patients and 6.3% (5/63) of controls reacted to L. infantum HSP70. Conclusion: The conservative nature of the HSP70 molecule is an advantage in vaccine studies, because of minor differences (6%) between the nucleotide sequences and consequently the similarity in amino acid sequences in various strains of L. infantum. It could therefore be used in vaccine research against leishmaniasis and also as a tool for serodiagnosis.
机译:背景:迄今为止,所有研究过的生物中都存在热休克蛋白70(HSP70),它是由利什曼原虫(Leishmania spp)等病原体引起的感染的主要免疫原。目的:本研究的目的是从婴儿乳杆菌MCAN / IR / 96 / LON-49克隆并表达HSP70,并评估针对内脏利什曼病(VL)的HSP70抗体反应。方法:用特异引物扩增婴儿乳杆菌HSP70基因片段。将其克隆到pTZ57R载体中,再亚克隆到pET32a(+)表达载体中。将新的构建体转化到大肠杆菌Rosetta菌株中,并在1 mM IPTG存在下表达HSP70蛋白,并使用HiTrap螯合柱进行纯化。通过ELISA测定了37例内脏利什曼病患者和63例健康对照者对HSP70的抗体反应。结果:使用SDS-PAGE电泳和抗His标签抗体的斑点印迹证实了HSP70蛋白的表达。在本研究中,HSP70基因的核苷酸序列与其他报道的序列之间没有差异。 ELISA结果表明,81.1%(30/37)的患者血清和6.3%(5/63)的对照血清对婴儿乳杆菌HSP70有反应。结论:HSP70分子的保守性质在疫苗研究中是一个优势,因为核苷酸序列之间的微小差异(6%),因此在各种婴儿乳杆菌中氨基酸序列的相似性。因此,它可用于抗利什曼病的疫苗研究,也可作为血清诊断的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号